Clinical features and prognostic factors in 49 patients with follicular lymphoma at a single center: A retrospective analysis

Table 1 Comparison of curative effects among different schemes, n (%)

Scheme	Number of cases	CR	PR	SD	PD	ORR (%)
I	14	3 (21.4)	4 (28.6)	5 (35.7)	2 (14.3)	50.0
II	32	11 (34.4)	13 (40.6)	3 (9.4)	5 (15.6)	75.0
III	3	1 (33.3)	2 (66.7)	0	0	100.00

CR: Complete remission; PR: Partial remission; SD: Stable disease; PD: Progressive disease; ORR: Objective remission rate.

Table 2 Correlation survival analysis of different risk groups, n (%)

Group	Risk factors	Cases, n (%)	3-year OS, % (SE)	3-year PFS, % (SE)	5-year OS, % (SE)	5-year PFS, % (SE)
Low risk	0–1	12 (24.5)	100	75.0 (0.18)	83.3 (0.12)	75.0 (0.18)
Medium risk	2	20 (40.8)	90.0 (0.08)	75.0 (0.08)	85.0 (0.11)	70.0 (0.16)
High risk	≥ 3	17 (34.7)	76.5 (0.10)	47.1 (0.13)	47.1 (0.13)	23.6 (0.20)

P < 0.05 compared with the other two groups. SE: Standard error; OS: Survival time; PFS:Progression-free survival.

Table 3 Clinical features and univariate prognosis of 49 patients with follicular lymphoma

Factors		3-year OS, % (SE)	5-year OS, % (SE)	Log-rank (P value)
Sex
	M (30)	86.7 (0.05)	63.3 (0.09)	0.185
	F (19)	78.9 (0.09)	63.1 (0.13)
Age (yr)
	≤ 60 (32)	84.3 (0.05)	71.9 (0.08)	0.584
	> 60 (17)	82.4 (0.08)	70.6 (0.13)
The presence or absence of B symptoms
	Y (31)	77.4 (0.08)	58.1 (0.13)	0.237
	N (18)	88.9 (0.06)	72.2 (0.09)
Stage
	I-II (17)	94.1 (0.05)	94.1 (0.05)	0.043
	III-IV (32)	78.1 (0.06)	65.6 (0.10)
Pathological grading
	I (3)	100.0	100.0	0.321
	II (16)	87.5 (0.07)	68.7 (0.12)
	III (30)	80.0 (0.05)	73.3 (0.11)
BM infiltration
	Y (10)	70.0 (0.13)	30.0 (0.15)	0.007
	N (39)	89.7 (0.04)	79.5 (0.08)
Involved lymph node area
	≤ 4 (36)	86.1 (0.05)	72.2 (0.08)	0.054
	> 4 (13)	76.9 (0.12)	53.8 (0.19)
Hepatomegaly
	Y (2)	100.0	100.0	0.835
	N (47)	85.1 (0.05)	74.4 (0.08)
Splenomegaly
	Y (10)	80.0 (0.10)	60.0 (0.14)	0.169
	N (39)	84.6 (0.05)	76.9 (0.09)
LDH
	Normal (14)	85.7 (0.10)	71.4 (0.10)	0.312
	High (35)	82.9 (0.05)	68.6 (0.09)
Hb
	< 120 g/L (20)	75.0 (0.09)	45.0 (0.12)	0.011
	≥ 120 g/L (29)	89.7 (0.04)	75.9 (0.09)
WBC
	≤ 4 × 109/L (11)	100	72.7 (0.18)	0.481
	> 4 × 109/L (38)	84.2 (0.05)	65.8 (0.08)
WBC
	≤ 10 × 109/L (42)	88.1 (0.05)	66.7 (0.08)	0.813
	> 10 × 109/L (7)	71.4 (0.21)	57.1 (0.21)
LYM
	≤ 1 × 109/L (25)	80.0 (0.09)	68.0 (0.15)	0.494
	> 1 × 109/L (24)	87.5 (0.05)	66.7 (0.09)
PLT
	≤ 80 × 109/L (9)	100	66.7 (0.19)	0.998
	> 80 × 109/L (40)	82.5 (0.06)	70.0 (0.08)
ALB
	≤ 35 g/L (6)	83.3 (0.15)	66.7 (0.19)	0.941
	> 35 g/L (43)	87.4 (0.05)	67.2 (0.08)
GLB
	≤ 34 g/L (44)	87.9 (0.05)	66.5 (0.08)	0.758
	> 34 g/L (5)	80.0 (0.18)	80.0 (0.18)
Ki-67
	≤ 50% (27)	96.2 (0.04)	91.3 (0.06)	0.004
	> 50% (22)	83.3 (0.15)	31.2 (0.25)
Bcl-6+	32	83.9 (0.07)	74.6 (0.09)	0.926
Bcl-6-	17	100	68.6 (0.19)
CD10+	35	85.7 (0.07)	64.6 (0.11)	0.293
CD10-	14	90.9 (0.09)	90.9 (0.09)
Bcl-2+	25	91.4 (0.06)	76.4 (0.09)	0.493
Bcl-2-	24	80 (0.10)	66.7 (0.15)

Statistical significance was set at P < 0.05. OS: Overall survival; Hb: Hemoglobin; PLT: Platelet; WBC: White blood cell; LYM: Lymphocyte; ALB: Albumin; GLB: Globulin; LDH: Lactate dehydrogenase; SE: Standard error.